ArticleThe oncologist2025
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Electroacupuncture enhances anti-tumor immunity in TNBC by reducing NE release and blocking α2-AR-mediated NGF/Hippo signaling.Chinese medicine · 2026Article
- Clinicopathological features, immunophenotyping, and immunohistochemical biomarkers associated with germline BRCA1/2 variants in breast cancer: a retrospective cohort of 265 patients.Scientific reports · 2026Article
- Investigation of Long Non-Coding RNAsNon-coding RNA · 2026Article
- Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives.Breast cancer (Dove Medical Press) · 2026Review
- Editorial: Molecular and functional profiling in breast cancer: implications for hereditary and sporadic cases.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent genetic screening for predisposition to breast cancer (BC) is limited to BRCA1/2 exons and intron/exon boundaries, and limited information exists about the impact of variants in BRCA1/2 non-coding regions. The majority of alterations identified in these regions remain unclassified, but evidence of the impact of variants in the regulatory regions on cancer risk and response to treatment is emerging. PATIENTS AND
methodsThis project aimed to investigate the prevalence of germline variants in the non-coding regulatory regions of BRCA1/2 and other BC predisposition genes in patients with triple-negative BC (TNBC) selected for age at cancer diagnosis and/or family history of cancer. The study also aims to investigate the relationship between these variants and clinical outcomes such as overall survival, disease-free survival (DFS), and response to treatment. We analyzed a Next-Generation Sequencing (NGS) custom panel of promoter regions of 28 genes involved in BC predisposition on 144 patients with TNBC previously tested wild type for coding regions of BRCA1/2.
resultsThe NGS analysis identified 635 rare variants in promoter regions of the 28 genes. Among the 144 patients, for 75 with available clinical data, rare germline variants in BRCA2 promoter were statistically significantly related to worse overall survival (OS) (P-value = .017). No differences in DFS and OS were found for the other genes. Rare variants in the CDH1 promoter were related to the highest percentage of non-pathological complete response after neoadjuvant chemotherapy (P = .0273); MLH1 and PALB2 rare non-coding variants were found to be both related to bilateral BC (P = .0146 and P = .0005, respectively) and ATM promoter variants were associated with a positive family history (P = .041).
conclusionOur results underscore the importance of searching for rare germline variants in regulatory regions of cancer predisposition genes in patients with TNBC, since these variants can be associated with an increased cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.